Skip to main content
. Author manuscript; available in PMC: 2012 Jul 24.
Published in final edited form as: Leukemia. 2008 Jan 24;22(4):783–790. doi: 10.1038/sj.leu.2405104

Figure 1.

Figure 1

High titers of anti-GM-CSF IgG are present in myeloid leukemia patients and are unaffected by vaccination with GM-CSF as an adjuvant. (a) Serum anti-GM-CSF IgG titers were evaluated by ELISA in vaccinated (n=19) and non-vaccinated (n=50) patients with myeloid leukemia and in a control group of patients with lymphoid leukemia (n=6) and HD (n=33). The results are the means of two experiments performed in duplicate; horizontal lines are column means. (b) Serum anti-GM-CSF IgG were evaluated in vaccinated patients (n=17) before the first vaccination and 3 weeks after the third vaccination. The lines connect results at different time points for each individual. Relative unit (RU): anti-GM-CSF reactivity of 1 μg IVIg. HD, healthy donors; Igs, immunoglobulins; ELISA, enzyme-linked immunosorbent assay; GM-CSF, granulocyte-macrophage colony-stimulating factor.